Discovery and Developmental Therapeutics

项目摘要/摘要 发现和发展治疗(DDT)计划提供了一个整合 Winship翻译管道的发现以及新的癌症诊断和开发 治疗方法的前提是滴滴涕之间的跨学科和跨学科互动 会员提出有效的抗癌策略。该计划围绕四个科学主题组织：(1) 治疗靶点和新型小分子的发现、发现和深入评估；(2)癌症 体内显像剂和技术的开发和/或利用，用于药物输送和治疗 非侵入性诊断和治疗癌症的应用；(3)癌症免疫治疗，翻译 创新的免疫概念和抗癌治疗方法；以及(4)发展治疗学， 采用新的治疗策略和个体化治疗方案的癌症人类介入试验 通过充当靶点、成像、治疗剂和 免疫疗法。这四个科学主题主导着方案的活动以及方案内和方案间 通过Winship提供的资源和基础设施进行研究。 在傅海安博士(负责人)和Suresh Ramalingam医学博士(共同负责人)的领导下，滴滴涕 该计划包括56名核心成员，代表医学院内的16个不同部门 (SOM)、罗林斯公共卫生学院(RSPH)和埃默里学院。从2012年到现在 高度合作的研究小组发表了1122篇与癌症相关的科学文章。其中，296人 (26%)是计划内协作，273(24%)是计划间协作，445(40%)涉及 与其他癌症中心或学术组织合作。截至2016年3月31日，滴滴涕成员 持有2,840万美元的年度癌症相关研究资金，由埃默里大学授予， 其中约980万美元(34%)直接来自NCI。此外，滴滴涕成员 Curran通过NRG肿瘤学基金会以多PI格式获得了1500万美元的NCI支持。已建成 关于Winship的使能资源和基础设施，以实现有效的药物和靶标发现及其 随后的翻译发展，并基于成员之间已有的互动，滴滴涕 该方案正在为开发有效的诊断和治疗方案做出重大贡献 为癌症患者准备的。

PROJECT SUMMARY/ABSTRACT The Discovery and Developmental Therapeutics (DDT) Program provides a platform for integration of discoveries into the Winship translational pipeline and for development of new cancer diagnostic and therapeutic approaches with the premise that interdisciplinary and transdisciplinary interactions among DDT members advance effective anti-cancer strategies. The program is organized around four scientific themes: (1) Discovery, the discovery and thorough evaluation of therapeutic targets and novel small molecules; (2) Cancer Imaging, the development and/or utilization of in vivo imaging agents and technologies for drug delivery and for non-invasive diagnostic and therapeutic cancer applications; (3) Cancer Immunotherapy, the translation of innovative immune concepts and approaches into anti-cancer therapies; and (4) Developmental Therapeutics, human interventional trials for cancer using novel therapeutic strategies and individualized treatment options by functioning as a convergence point for translation of targets, imaging, therapeutic agents, and immunotherapies. These four scientific themes lead the program's activities and intra- and inter-programmatic research efforts through resources and infrastructure provided by Winship. Under the leadership of Haian Fu, PhD (leader) and Suresh Ramalingam, MD (co-leader) the DDT Program includes 56 core members representing 16 different departments within the School of Medicine (SOM), Rollins School of Public Health (RSPH), and Emory College. Between 2012 and the present this highly collaborative group of researchers published 1,122 cancer-relevant scientific articles. Of these, 296 (26%) were intra- and 273 (24%) were inter-programmatic collaborations, and 445 (40%) involved a collaboration with another cancer center or academic organization. As of March 31, 2016, DDT members held $28.4 million in annual total cancer-relevant research funding as awarded through Emory University, of which approximately $9.8 million (34%) was awarded directly from the NCI. In addition, DDT member Curran received $15M of NCI support as PI in a multi-PI format through the NRG Oncology Foundation. Built on Winship's enabling resources and infrastructure for effective drug and target discovery and their subsequent translational development and based on established interactions among members, the DDT Program is making major contributions to the development of efficacious diagnostic and treatment options for cancer patients.